Alejandro López Targa Institutions of which they are part Tècnic/a Grau Superior International Unit Competitive Research Directorate Vall Hebron Institut de Recerca Email Alejandro López Targa Email Institutions of which they are part Tècnic/a Grau Superior International Unit Competitive Research Directorate Vall Hebron Institut de Recerca
Projects Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia IP: Rafael Simó Canonge Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Jaume Rigo Quera, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Queralt Martin Saladich, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Alejandro López Targa, Patricia Bogdanov Baruj, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Andreea Ciudin Mihai, Ferran Casals Riera Funding agency: EUROPEAN COMMISSION Funding: 950410 Reference: RECOGNISED_H2020SC1BHC2019 Duration: 01/01/2020 - 31/12/2024 SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.. IP: SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.. Collaborators: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Belen Garcia Prats, Angels Alcina Mila, Alejandro López Targa, Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro Funding agency: EUROPEAN COMMISSION Funding: 649580 Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018 Duration: 01/04/2019 - 30/09/2023 Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease. GRANT AGREEMENT NO: 634579 IP: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholi Collaborators: Alejandro López Targa, Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholi Funding agency: EUROPEAN COMMISSION Funding: 93750 Reference: CARBALIVE_H2020-PHC2014 Duration: 01/05/2015 - 31/01/2021 Pagination First page « Previous page ‹ Page 1 Current page 2
